Ludwig Institute for Cancer Research Limited

Wyeth

Universitè Catholique De Louvain

Argenx Bvba

Argenx Bv

Laure Dumoutier

Jean-Christophe Renauld

Jamila Louhed

Pierre G Coulie

Sophie Lucas

Julia Cuende Villasur

Hans De Haard

Sebastian Paul Van Der Woning

Michael Saunders

Gitte De Boeck

Jamila Louahed

Diane Lejeune

Helmut Fickenscher

Simon Hör

The present invention relates to a protein binding to GARP in the presence of TGF-&#x3b2; and uses thereof.

Anti-GARP protein

Antibody against a complex between human GARP and latent TGF-&#x3b2;

The present invention relates to an antibody binding to the transmembrane protein 'glycoprotein A repetitions predominant' (GARP) in the presence of TGF-&#x3b2; and uses thereof.

Method for inhibiting the immune suppressive function of human T regulatory cells by administering an anti-GARP monoclonal antibody

The invention involves isolation of nucleic acid molecules, the expression of which are upregulated by interleukin-9. The amino acid sequences of the proteins which correspond to the nucleic acid molecules show some structural features of cytokines. In addition to the nucleic acid molecules and the proteins, various uses of the molecules are disclosed. The molecules are referred to as T cell inducible factors.

Isolated nucleic acid molecules which encode T cell inducible factors (TIFs), the proteins encoded, and uses thereof

Interleukin-22 interacts with its receptor, referred to as IL-22R, and instigates a series of reactions, leading to activation of various molecules, such as JAK-1, Tyk2, and others. One can identify molecules which mediate this interaction by measuring the activity of one or more of the molecules in the pathway, to identify agonists and antagonists. These, in turn, are useful therapeutic agents, where inappropriate expression of one of the activated molecules is at issue, and requires amelioration.

Method for identifying a substance which mediates interaction between interleukin 22 and an interleukin 22 receptor

The invention relates to soluble proteins which bind to the molecule known as IL-TIF/IL-22. The proteins can antagonize the effect of IL-TIF/IL-22 on target cells. The nucleic acid molecules encoding the proteins, and uses of the protein, are also described.

Isolated nucleic acid molecules which encode a soluble IL-TIF receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof

Isolated nucleic acid molecules encoding T cell derived inducible factors

The invention relates to new members of the Class II cytokine receptor family, such as LICR-2. The new member binds to AK155, and mediates STAT activation.

Isolated cytokine receptor LICR-2

Isolated nucleic acid molecules which encode T cell inducible factors (TIFs), the proteins encoded, and uses therefor

Isolated nucleic acid molecules which encode T cell inducible factors (TIFS), the proteins encoded, and uses thereof

The invention involves isolation of nucleic acid molecules, the expression of which are upregulated by interleukin-9. The amino acid sequences of the proteins which correspond to the nucleic acid molecules show some structural features of cytokines. In addition to the nucleic acid molecules and the proteins, various uses of the molecules are disclosed. The molecules are referred to as T cell induceable factors.

Antibodies which specifically bind T Cell inducible factors (TIFs)

Growing community of inventors

Brussels, Belgium

Laure Dumoutier